Joshua Resnick

Joshua Resnick is a Partner and Senior Managing Director at RA Capital Management, where he invests from seed through late-stage and post-IPO equity across healthcare, life sciences, biotechnology, medical devices, diagnostics, and research tools, primarily in the United States with a focus on the Greater Boston and East Coast regions. He serves on the boards of Synolo Therapeutics, Stylus Medicine, TRIANA Biomedicines, and Sionna Therapeutics, and has invested in companies like Vor Biopharma, Be Biopharma, Sionna Therapeutics, Mariana Oncology, and Bright Peak Therapeutics. Previously, he held roles as Senior Managing Director and Managing Director at RA Capital Management; Co‑Founder and President of Raven (RA Ventures); Attending Physician in the Department of Emergency Medicine at Massachusetts General Hospital; Co‑Founder and Board Member at Aliada Therapeutics and Mariana Oncology; and Founder, Chair, and CEO of Caraway Therapeutics (formerly Rheostat). Joshua earned degrees from Williams College, the University of Pennsylvania School of Medicine, and The Wharton School, and he is based in Boston, Massachusetts.